Forge’s lead program LpxC, a zinc metalloenzyme, has been recognized as an attractive antibacterial target for more than 15 years as it is conserved across Gram-negative bacteria and not found in Gram-positive or human cells. However, lack of suitable chemical starting points has hampered development progress. With our BLACKSMITH platform, Forge has generated potent inhibitors of LpxC that are safe and effective in animal models of Gram-negative infection and are able to kill Gram-negative ‘superbugs’ where other antibiotics are ineffective.
At Forge Therapeutics, we have utilized our innovative drug discovery BLACKSMITH platform to identify selective metal-binding pharmacophore fragments. Then, using bioinorganic and medicinal chemistry principles, we develop potent full-length inhibitors through a novel fragment growth strategy incorporating computational and structural biology. Current pipeline efforts are focused on developing new antibacterial agents.
Partially funded or Partnership:
E. coli, K. pneumoniae, P. mirabilis
Y. pestis, F. tularensis, B. mallei, B. pseudomallei